Is Opthotech Your Next Multibagger Stock?

Opthotech is working on a treatment for wet AMD that could have sales potential equal to that of Novartis' Lucentis or Regeneron's (REGN) Eylea.

Jul 8, 2014 at 5:00PM

Opthotech (NASDAQ:OPHT) has had quite a run in the past two years. Shares have nearly doubled as investors have grown increasingly confident that Fovista, its treatment for wet age-related macular degeneration, can eventually reach the market.

If it does, Opthotech investors may find that the stock is significantly undervalued relative to Regeneron (NASDAQ:REGN), the maker of the highly successful wet-AMD treatment Eylea.


Source: Regeneron.

A big-time deal
Opthotech has retreated from a 20% jump in May that followed the announcement of a significant partnership deal with Novartis (NYSE:NVS).

Novartis paid Opthotech an impressive $200 million up front to partner with it on Fovista and agreed to milestone payments that could eventually total $1 billion, plus royalties on any sales.

For that much money, you'd think Novartis had locked up global rights to the drug, but it didn't. The deal only covers ex-U.S. sales of Fovista and clearly suggests that Novartis believes Opthotech has a big blockbuster on its hands.

Despite that vote of confidence, Opthotech's market cap remains just a shade over $1 billion -- about as much as Novartis may potentially pay in milestones alone.

Why Novartis wants Fovista
Wet AMD is an increasingly important market for drugmakers. Baby boomers are turning 65 at a pace of 10,000 people per day, and that will significantly increase demand for treatments targeting this age-related disease.


Source: Novartis.

AMD is the leading cause of vision loss among those over 50, and more than 15 million Americans are diagnosed with the condition. Roughly 10% of those patients have the severe form of the disease that Fovista is being developed to treat.

Treating those patients can involve laser coagulation or treatment with specially designed eye drugs such as Regeneron's Eylea and Roche and Novartis' Lucentis.

In 2013, Regeneron's Eylea sales totaled more than $1.4 billion in the U.S., and sales continued to grow in the first quarter, rising 14% year over year to $359 million.

Sales are also climbing overseas for Regeneron's partner, Bayer. International sales reached $472 million in 2013 (its first full year on the market) and totaled $218 million in the first quarter, up from $62 million the year before.

Novartis, which owns the ex-U.S. rights to Lucentis, notched nearly $2.4 billion in sales from the drug last year, and roughly three-quarters of those sales are tied to the wet-AMD indication.

Roche, which markets the drug in the U.S., also reported strong sales, totaling $500 million in the first quarter.

Rather than displace those drugs, Opthotech is pairing Fovista with them to show that using Fovista in combination with them can improve vision more than using Eylea and Lucentis alone. In phase 2 trials, combining Fovista with Lucentis improved vision by 10.6 letters on a standard eye chart, versus just 6.5 letters for Lucentis alone.


Source: Opthotech. PDGF = platelet-derived growth factor. VDGF = vascular endothelial growth factor.

Fool-worthy final thoughts
According to the National Institutes of Health, more than 8 million Americans are at risk of developing AMD and 150,000 people in the U.S. are diagnosed with wet-AMD every year.

That suggests that there's a big and growing market for new treatments, and while results from Opthotech's phase 3 trial won't be available until 2016, I'm keeping a close eye on this one, given that Regeneron's market cap is nearly 30 times larger than Opthotech, and Opthotech's market cap doesn't seem to reflect any potential revenue beyond Novartis' milestones.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and with more accuracy than anyone else. There's a product in development that will revolutionize how we treat a common chronic illness and could even change the entire health industry. Analysts are already licking their chops at the sales potential. To outsmart Wall Street and realize multibagger returns, you need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. Click here now.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers